



Express Mail Label No. EL953455462US

PATENT
Attorney Docket No. LEX-002C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Gillies et al.
SERIAL NO.: 10/005,212 GROUP NO.: 1646
FILING DATE: December 4, 2001 EXAMINER: Not Yet Assigned
TITLE: HETERODIMERIC FUSION PROTEINS USEFUL FOR TARGETED
IMMUNE THERAPY AND GENERAL IMMUNE STIMULATION

Commissioner for Patents
Washington, D.C. 20231

SECOND PRELIMINARY AMENDMENT

Sir:

Please enter the following Preliminary Amendment for the above-identified continuation patent application.

AMENDMENTS

Prior to substantive examination, kindly amend the application as follows.

In the claims:

Please cancel claims 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 and 22 without prejudice.

REMARKS

After entry of this Preliminary Amendment, claims 1, 2, 3, 23, and 24 are pending in the Application. Applicants have canceled claims 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 19, 20, 21 and 22 without prejudice and without any intention to abandon the subject matter as filed, but with the intention that claims of the same, greater, or lesser scope may be pursued in this or a continuing application. Applicants respectfully submit that no new matter is introduced by the amendment.